

Appl. No. 10/796,529
Amdt. dated March 21, 2007
Reply to Office Action of September 21, 2006

RECEIVED
CENTRAL FAX CENTER
MAR 21 2007

Amendments to the Claims

This listing of claims will replace all prior versions, or listings, of claims in this application.

Listing of Claims:

Claims 1-38 (cancelled)

Claim 39 (Previously presented): A method for the treatment of a HCV infection in a host in need thereof comprising administering an effective treatment amount of a β -D-2'-fluoronucleoside, or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 40 (Previously presented): The method of claim 39, wherein the β -D-2'-fluoronucleoside has a pyrimidine base.

Claim 41 (Previously presented): The method of claim 40, wherein the pyrimidine base is selected from the group consisting of thymine, uracil, 5-halouracil, 5-fluorouracil, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-aza-pyrimidine, 6-azacytosine, 2- and/or 4-mercaptopyrimidine, C⁵-alkylpyrimidine, C⁵-benzylpyrimidine, C⁵-halopyrimidine, C⁵-vinylpyrimidine, C⁵-acetylenic pyrimidine, C⁵-acyl pyrimidine, C⁵-hydroxyalkyl purine, C⁵-amidopyrimidine, C⁵-cyanopyrimidine, C⁵-nitropyrimidine, and C⁵-aminopyrimidine.

Claim 42 (Previously presented): The method of claim 40, wherein the pyrimidine base is thymine.

Claim 43 (Previously presented): The method of claim 40, wherein the pyrimidine base is uracil.

Claim 44 (Previously presented): The method of claim 40, wherein the pyrimidine base is 5-halouracil.

Claim 45 (Previously presented): The method of claim 40, wherein the pyrimidine base is cytosine.

Appl. No. 10/796,529

Amdt. dated March 21, 2007

Reply to Office Action of September 21, 2006

Claim 46 (Previously presented): The method of claim 40, wherein the pyrimidine base is 5-fluorocytosine.

Claim 47 (Previously presented): The method of claim 39, wherein the β -D-2'-fluoronucleoside has a purine base.

Claim 48 (Previously presented): The method of claim 47, wherein the purine base is selected from the group consisting of N⁶-alkylpurine, N⁶-acylpurine (wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N⁶-benzylpurine, N⁶-halopurine, N⁶-vinylpurine, N⁶-acetylenic purine, N⁶-acyl purine, N⁶-hydroxyalkyl purine, N⁶-thioalkyl purine, N²-alkylpurines, N²-alkyl-6-thiopurines, N²-alkylpurine, N²-alkyl-6-thiopurine, 5-azacytidinyl, guanine, adenine, hypoxanthine, 2,6-diaminopurine, and 6-chloropurine.

Claim 49 (Previously presented): The method of claim 39, wherein the β -D-2'-fluoronucleoside has a triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, or pyrazolopyrimidinyl base.

Claim 50 (Previously presented): The method of claim 39, wherein the β -D-2'-fluoronucleoside is in substantially pure form.

Claim 51 (Previously presented): The method of claim 39, wherein the β -D-2'-fluoronucleoside is at least 90% by weight of the β -D-isomer.

Claim 52 (Previously presented): The method of claim 39, wherein the β -D-2'-fluoronucleoside is at least 95% by weight of the β -D-isomer.

Claim 53 (Previously presented): The method of claim 39, wherein the β -D-2'-fluoronucleoside is administered in the form of a dosage unit.

Claim 54 (Previously presented): The method of claim 53, wherein the dosage unit contains 50-1000 mg of the compound.

Claim 55 (Previously presented): The method of claim 53, wherein the dosage unit is in the form of a tablet or capsule.

Claim 56 (Previously presented): The method of claim 39, wherein the pharmaceutically acceptable carrier is suitable for oral delivery.

Appl. No. 10/796,529

Amdt. dated March 21, 2007

Reply to Office Action of September 21, 2006

Claim 57 (Previously presented): The method of claim 39, wherein the pharmaceutically acceptable carrier is suitable for intravenous delivery.

Claim 58 (Previously presented): The method of claim 39, wherein the pharmaceutically acceptable carrier is suitable for parenteral delivery.

Claim 59 (Previously presented): The method of claim 39, wherein the pharmaceutically acceptable carrier is suitable for intradermal delivery.

Claim 60 (Previously presented): The method of claim 39, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous delivery.

Claim 61 (Previously presented): The method of claim 39, wherein the pharmaceutically acceptable carrier is suitable for topical delivery.

Claim 62 (Previously presented): The method of any one of claims 39-49, wherein the host is a human.